US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by bioAffinity Technologies, Inc.

< Previous 1 2 3 4 Next >
News headline image
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Reports First Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
News headline image
bioAffinity Technologies Announces Closing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
News headline image
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
< Previous 1 2 3 4 Next >